A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

Targeted Oncology

Volumn 11, Issue 3, 2016, Pages 293-308

  Loupakis, Fotios ^a   Stein, Alexander ^b   Ychou, Marc ^c   Hermann, Frank ^d   Salud, Antonieta ^e   Österlund, Pia ^f  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CENTRE VAL D AURELLE   (France)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT;

ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; BLEEDING; BRAIN DISEASE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FISTULA; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; LEUKOPENIA; LIVER METASTASIS; LUNG HEMORRHAGE; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHRITIS; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TRIPLET CHEMOTHERAPY; VENOUS THROMBOEMBOLISM; VOMITING; WOUND DEHISCENCE; COLORECTAL NEOPLASMS; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 84950275691     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0400-y     Document Type: Article

References (87)

1. Penna C, Nordlinger B (2002) Colorectal metastasis (liver and lung). Surg Clin N Am 82:1075–90, x–xi
2. Castellanos JA, Merchant NB (2014) Strategies for management of synchronous colorectal metastases. Curr Surg Rep 2:62
3. Howlader N, Noone AM, Krapcho M, et al (eds) (2014) SEER cancer statistics review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. SEER Stat Fact Sheets: Colon and rectum cancer. Available from: http://seer.cancer.gov/statfacts/html/colorect.html.
4. National Comprehensive Cancer Network (2015) Clinical practice guidelines in oncology (NCCN guidelines): colon cancer, version 2.2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
5. Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–9
6. Smith JJ, D'Angelica MI (2015) Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin N Am 29:61–84
7. Jones RP, Malik HZ, Fenwick SW et al (2013) Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol 39:807–11
8. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–47
9. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–7
10. Falcone A, Masi G, Vasile E et al (2009) FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs. FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis. Ann Oncol 20(suppl 8):348, Abstract P-6085
11. Falcone A, Masi G, Allegrini G et al (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006–14
12. Masi G, Allegrini G, Cupini S et al (2004) First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 15:1766–72
13. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ouest. J Clin Oncol 25:1670–6
14. Souglakos J, Androulakis N, Syrigos K et al (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798–805
15. Ychou M, Conroy T, Seitz JF et al (2003) An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 14:481–9
16. Ychou M, Viret F, Kramar A et al (2008) Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 62:195–201
17. Ychou M, Rivoire M, Thezenas S et al (2013) A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 20:4289–97
18. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47
19. Tan BR, Zubal B, Hawkins W, et al (2009) Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Presented at: 2009 gastrointestinal cancers symposium; January 15–17, 2009; San Francisco, CA. Abstract 497.
20. Douillard JY, Siena S, Cassidy J et al (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25:1346–55
21. Sorich MJ, Wiese MD, Rowland A et al (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:13–21
22. Ye LC, Liu TS, Ren L et al (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31:1931–8
23. Van Cutsem E, Lenz HJ, Köhne CH et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692–700
24. Avastin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2014.
25. Avastin EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000582/WC500029260.pdf.
26. Cetuximab [prescribing information]. Bridgewater, NJ: Imclone LLC; 2015.
27. Panitumumab [prescribing information] Thousand Oaks, CA: Amgen, Inc; 2015.
28. Cetuximab EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf.
29. Panitumumab EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000741/WC500047710.pdf.
30. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–42
31. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–9
32. Folprecht G, Hamann S, Schütte K et al (2014) Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer 14:521
33. Garufi C, Torsello A, Tumolo S et al (2010) Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103:1542–7
34. Fornaro L, Lonardi S, Masi G et al (2013) FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ouest (GONO). Ann Oncol 24:2062–7
35. Saridaki Z, Androulakis N, Vardakis N et al (2012) A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 107:1932–7
36. Assenat E, Desseigne F, Thezenas S et al (2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16:1557–64
37. Gruenberger T, Bridgewater J, Chau I, et al (2014) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2014 Dec 23.
38. Stein A, Glockzin G, Wienke A, Arnold D et al (2012) Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer 12:356
39. Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609–18
40. Cremolini C, Loupakis F, Antoniotti C, et al (2015) Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ouest. Ann Oncol 2015 Feb 23.
41. Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. doi:10.1016/S1470-2045(15)00122-9
42. Nipp RD, Ryan DP (2015) Should FOLFOXIRI plus bevacizumab be the standard first-line therapy in metastatic colorectal cancer? Oncologist 20:236–8
43. Masi G, Loupakis F, Salvatore L et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11:845–52
44. Stein A, Atanackovic D, Hildebrandt B, Stübs P et al (2015) Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer 113:872–7
45. Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–75
46. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830–5
47. Loupakis F, Schirripa M, Caparello C et al (2013) Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 108:2549–56
48. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106
49. Vale CL, Tierney JF, Fisher D et al (2011) Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 38:618–25
50. Pietrantonio F, Petrelli F, Coinu A et al (2015) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51:587–94
51. Rowland A, Dias MM, Wiese MD et al (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112:1888–94
52. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–72
53. Bokemeyer C, Van Cutsem E, Rougier P et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466–75
54. Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–34
55. Loupakis F, Cremolini C, Salvatore L et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50:57–63
56. Hebbar M, Chibaudel B, André T et al (2013) Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. J Chemother 25:104–11
57. Hurwitz H, Tan B, Reeves J, et al (2014) Interim safety results from STEAM: a randomized phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs. FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 25(suppl 4): poster 521-P.
58. Falcone A, Cremolini C, Masi G, et al (2013) FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group. J Clin Oncol 31(Suppl): abstract 3505.
59. National Cancer Institute (2015) Gastrointestinal complications (PDQ): diarrhea. Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional/page5.
60. Camptosar [prescribing information]. New York, NY: Pflzer, Inc; 2012.
61. Maroun JA, Anthony LB, Blais N et al (2007) Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 14:13–20
62. Eloxatin [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2014.
63. Benson AB III, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment–induced diarrhea. J Clin Oncol 22:2918–26
64. BCCA guidelines for the management of chemotherapy-induced diarrhea. Available from: http://www.bccancer.bc.ca/nr/rdonlyres/4e7ef86a-eaa5-4f3c-b147-b2512799f6b3/7371/guidelinesformanagementofcid.pdf.
65. Mini E, Nobili S (2009) Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 6:17–24
66. Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6:207–18
67. Caudle KE, Thorn CF, Klein TE et al (2013) Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94:640–5
68. Arbuckle RB, Huber SL, Zacker C (2000) The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5:250–9
69. National Institutes of Health (2010) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
70. McQuade RM, Bornstein JC, Nurgali K (2014) Anti-colorectal cancer chemotherapy-induced diarrhoea: current treatments and side-effects. Int J Clin Med 5:393–406
71. Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:e447–60
72. Eberlin M, Mück T, Michel MC (2012) A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol 3:93
73. Wang H, Geier MS, Howarth GS (2014) Prebiotics: a potential treatment strategy for the chemotherapy-damaged gut? Crit Rev Food Sci Nutr 2014 Aug 27.
74. Prisciandaro LD, Geier MS, Butler RN, Cummins AG et al (2011) Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis. Crit Rev Food Sci Nutr 51:239–47
75. Redman MG, Ward EJ, Phillips RS (2014) The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 25:1919–29
76. Österlund P, Ruotsalainen T, Korpela R et al (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97:1028–34
77. Gibson RJ, Keefe DM, Lalla RV et al (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21:313–26
78. National Cancer Institute. Nausea and vomiting (PDQ) (2015) Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional.
79. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–43
80. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 29:4189–98
81. Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group (2011) Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 22(Suppl 6):vi78–84
82. Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–61
83. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529–41
84. Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3:1477–84
85. Ramsey SD, McCune JS, Blough DK et al (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16:678–86
86. Gupta S, Singh PK, Bhatt ML et al (2010) Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends 4:273–8
87. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2004) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure – complete report. Available from: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm.